DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2+mBC

被引：0
|
作者：
Andre, Fabrice
Hamilton, Erika P.
Loi, Sherene
Anders, Carey K.
Schmid, Peter
Stroyakovskiy, Daniil
Villanueva, Rafael
Pedrini, Jose Luiz
Doval, Dinesh Chandra
Zurawski, Bogdan
Chen, Shin-Cheh
Boston, Sarice Renee
Konpa, Adam
Pierotti, Barbara
Fabbri, Giulia
Jhaveri, Komal L.
机构：
[1] Univ Paris Saclay, Gustave Roussy, Villejuif, France
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Peter MacCallum Canc Ctr, Melbourne, Australia
[4] Duke Canc Inst, Durham, NC USA
[5] Queen Mary Univ London, Barts Canc Inst, London, England
[6] Moscow City Oncol Hosp 62, Moscow, Russia
[7] ICO Hosp, Barcelona, Spain
[8] Nossa Senhora Conceicao Hosp, Porto Alegre, Brazil
[9] Rajiv Gandhi Canc Inst & Res Ctr, New Delhi, India
[10] F Lukaszczyk Oncol Ctr, Bydogoszcz, Poland
[11] Linkou Chang Gung Mem Hosp, Dept Gen Surg & Breast Surg, Taoyuan, Taiwan
[12] AstraZeneca, Gaithersburg, MD USA
[13] AstraZeneca, Warsaw, Mazowieckie, Poland
[14] AstraZeneca, Boston, MA USA
[15] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1009
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01,-02, and-03
    Hurvitz, S. A.
    Modi, S.
    Li, W.
    Park, Y. H.
    Chung, W.
    Kim, S-B.
    Cortes, J.
    Yamashita, T.
    Pedrini, J.
    Im, S-A.
    Tseng, L-M.
    Harbeck, N.
    Krop, I.
    Curigliano, G.
    Mathias, E.
    Cathcart, J.
    Cagnazzo, A.
    Ashfaque, S.
    Egorov, A.
    Andre, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S335 - S336
  • [22] Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07)
    Hamilton, Erika
    Jhaveri, Komal
    Loi, Sherene
    Anders, Carey
    Schmid, Peter
    Penkov, Konstantin
    Artamonova, Elena
    Zhukova, Lyudmila
    Stroyakovsky, Daniil L.
    Doval, Dinesh Chandra
    Villanueva, Rafael
    Michelini, Flavia
    Chandarlapaty, Sarat
    Wilson, Matt
    Boston, Sarice R.
    Konpa, Adam
    Mondal, Shoubhik
    Andre, Fabrice
    CANCER RESEARCH, 2023, 83 (05)
  • [23] A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC)
    Kumar, Prashanth Ashok
    Sandhu, Michael
    Sravanthi, Metlapalli Venkata
    Kumar, Vishnu Charan Suresh
    Benjamin, Sam
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
    Cortes, J.
    Kim, S-B.
    Chung, W-P.
    Im, S-A.
    Park, Y. H.
    Hegg, R.
    Kim, M. H.
    Tseng, L-M.
    Petry, V.
    Chung, C-F.
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Verma, S.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1287 - S1288
  • [25] Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
    Powell, C. A.
    Modi, S.
    Iwata, H.
    Takahashi, S.
    Nie, K.
    Qin, A.
    Singh, J.
    Taitt, C.
    Verma, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S61 - S62
  • [26] A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03).
    Janjigian, Yelena Y.
    Viglianti, Natasha
    Liu, Feng
    Mendoza-Naranjo, Ariadna
    Croydon, Liz
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [27] A phase Ib/II, multicenter, open-label, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd; DS8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03)
    Janjigian, Y. Y.
    Viglianti, N.
    Liu, F.
    Mendoza-Naranjo, A.
    Puvvada, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S930 - S931
  • [28] Rescue Therapy with Trastuzumab Deruxtecan (T-Dxd) in Patients with primary hepatic metastatic Her2 low Breast Cancer with marked Hyperbilirubinemia
    Wolf, M.
    Sili, F.
    Sulejmani, V.
    Schuepferling, A.
    Bomhard, J.
    Huber, M.
    Sigl, S.
    Schnelzer, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (06) : E44 - E44
  • [29] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
    Meric-Bernstam, Funda
    Makker, Vicky
    Oaknin, Ana
    Oh, Do-Youn
    Banerjee, Susana N.
    Martin, Antonio Gonzalez
    Jung, Kyung Hae
    Lugowska, Iwona A.
    Manso, Luis
    Manzano, Aranzazu
    Melichar, Bohuslav
    Siena, Salvatore
    Stroyakovskiy, Daniil
    Anoka, Chiedozie
    Ma, Yan
    Puvvada, Soham D.
    Lee, Jung-Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA3000 - LBA3000
  • [30] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results
    Lin, N.
    Ciruelos, E. M.
    Jerusalem, G.
    Mueller, V.
    Niikura, N.
    Viale, G.
    Bartsch, R.
    Kurzeder, C.
    Connolly, R.
    Baron-Hay, S. E.
    Cortes, M. Gion
    Guarneri, V.
    Bianchini, G.
    Wildiers, H.
    Escriva-de-Romani, S.
    Prahladan, M.
    Bridge, H.
    Verma, S.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2024, 35 : 1211 - 1212
12345